Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Studio CARUSO: carotid plaque stabilization and regression with evolocumab
2024-518566-27-00Phase 4Authorised
- Sponsor
- Azienda Ospedaliera Ordine Mauriziano di Torino
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of evolocumab in carotid atheroma (CAS) (2 arms), sponsored by Azienda Ospedaliera Ordine Mauriziano di Torino. Primary endpoints: Morphological stabilization of carotid plaque at 6 months and Regression of carotid plaque at 12 months. Planned start Jan 2025; status: authorised.
02
Drugs
evolocumab
03
Conditions
carotid atheroma (CAS)
Beyond the preview
Go deeper on 2024-518566-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518566-27-00.